Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05549323 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

A Phase 1 study, sponsored by Pfizer.

Terminated
Registry status
Phase 1
Development phase
44
Enrollment target

NCT05549323: Clinical Trial Phase 1 study, sponsored by Pfizer.

NCT05549323 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05549323, a Phase 1 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 1
Development phase
44 participants
Enrollment target

Study Summary

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

Primary Outcome

Clinical remission based on modified Mayo Score is defined as endoscopic subscore equal 0 or 1 (without friability), stool frequency subscore equal 0 or 1, and rectal bleeding subscore equal 0

Interventions

  • DRUG Placebo
  • DRUG PF-07054894

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2022-11-07
Est. Completion 2025-11-11
Phase Phase 1
Pfizer

1,845 total trials

Why NCT05549323 stopped before completion

NCT05549323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05549323 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05549323 about?

NCT05549323 is a clinical study titled "A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis". This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

What is the current status of trial NCT05549323?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-11-07. Estimated completion is 2025-11-11.

What interventions are being tested in trial NCT05549323?

The interventions under investigation include: Placebo (DRUG), PF-07054894 (DRUG).

Who is sponsoring clinical trial NCT05549323?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05549323's enrollment target sits among peer trials

44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05549323, the US trial registry maintained by the National Library of Medicine. NCT05549323 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.